Institutional shares held 118 Million
308K calls
191K puts
Total value of holdings $19.7B
$51.6M calls
$32M puts
Market Cap $16.7B
96,957,400 Shares Out.
Institutional ownership 121.26%
# of Institutions 538


Latest Institutional Activity in NTRA

Top Purchases

Q4 2024
Assenagon Asset Management S.A. Shares Held: 325K ($55.9M)
Q4 2024
Kbc Group Nv Shares Held: 27.6K ($4.74M)
Q4 2024
Rockingstone Advisors LLC Shares Held: 16.3K ($2.81M)
Q4 2024
Donoghue Forlines LLC Shares Held: 12.8K ($2.2M)
Q4 2024
Narwhal Capital Management Shares Held: 6.5K ($1.12M)

Top Sells

Q4 2024
Artemis Investment Management LLP Shares Held: 129K ($22.2M)
Q4 2024
Zweig Di Menna Associates LLC Shares Held: 229K ($39.4M)
Q4 2024
Exchange Traded Concepts, LLC Shares Held: 5.59K ($961K)
Q4 2024
First Hawaiian Bank Shares Held: 14.2K ($2.44M)
Q4 2024
Harbor Capital Advisors, Inc. Shares Held: 14.2K ($2.43M)

About NTRA

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.


Insider Transactions at NTRA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
2.29M Shares
From 25 Insiders
Grant, award, or other acquisition 643K shares
Exercise of conversion of derivative security 1.54M shares
Bona fide gift 111K shares
Sell / Disposition
1.59M Shares
From 14 Insiders
Open market or private sale 1.47M shares
Bona fide gift 123K shares

Track Institutional and Insider Activities on NTRA

Follow Natera, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTRA shares.

Notify only if

Insider Trading

Get notified when an Natera, Inc. insider buys or sells NTRA shares.

Notify only if

News

Receive news related to Natera, Inc.

Track Activities on NTRA